The Technical Analyst
Sensei Biotherapeutics, [SNSE]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Sensei Biotherapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.29% $1.005
/ 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 25.20 mill |
| EPS: | -1.220 |
| P/E: | -0.820 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 25.07 mill |
| Avg Daily Volume: | 0.0710 mill |
| RATING 2024-04-15 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.820 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.820 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.243 (-75.78%) $-0.762 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.906 - 1.094 ( +/- 9.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-15 | Van Der Horst Edward | Buy | 125 000 | Stock Option (Right to Buy) |
| 2024-02-15 | Van Der Horst Edward | Buy | 90 102 | Stock Option (Right to Buy) |
| 2024-02-15 | Van Der Horst Edward | Sell | 2 843 | Common Stock |
| 2024-02-15 | Celebi John | Buy | 315 000 | Stock Option (Right to Buy) |
| 2024-02-15 | Celebi John | Buy | 165 889 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -28.78 |
| Last 90 transactions |
| Buy: 2 519 843 | Sell: 4 237 046 |
Forecast:
16:00 - $1.005
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.005
Forecast 2: 16:00 - $1.005
Forecast 3: 16:00 - $1.005
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.005 (-4.29% ) |
| Volume | 0.0356 mill |
| Avg. Vol. | 0.0710 mill |
| % of Avg. Vol | 50.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SNSE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SNSE
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 07:30:00 - Press Release
Sensei Biotherapeutics To Participate In Canaccord Genuity's Horizons In Oncology Virtual Conference
Boston, april 09, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that company management will participate in a panel titled ‘kras and vista - better approaches for key targets' at canaccord genuity's horizons in oncology virtual conference on monday, april 15th at 2:00 p.m. et.
2024-04-04 16:05:00 - Press Release
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism Of Action Of Sns-101 Selectively Targeting The Active Form Of Vista Within The Tumor Microenvironment
Boston, april 04, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in nature communications. the research was conducted by scientists at sensei biotherapeutics in collaboration with genoway and the laboratory of dr. robert schreiber at the washington university, st. louis school of medicine.
2024-03-22 07:30:00 - Press Release
Sensei Biotherapeutics To Participate In The 3rd Annual Vista Symposium
Boston, march 22, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that company management will participate on a panel titled ‘anti-vista immunotherapies in clinical development' at the 3rd annual vista symposium. the vista symposium will convene scientific experts and industry leaders to explore the important emerging role of vista in cancer immunotherapy and will review the latest insights on vista biology, the growing potential of vista as a therapeutic target in multiple cancer indications and share updates on the ongoing clinical development of anti-vista therapies...
2024-03-06 07:30:00 - Press Release
Sensei Biotherapeutics To Present New Preclinical Data At Upcoming Scientific Conferences
Boston, march 06, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
2024-02-28 07:30:00 - Press Release
Sensei Biotherapeutics Reports Full Year 2023 Financial Results And Recent Business Highlights
- updated dose escalation data from sns-101 clinical study supports favorable and potentially best-in-class safety and pk profile both as monotherapy and in combination with pd-1 blockade -
Latest News
2024-04-09 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets' at Canaccord Genuity's Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.
2024-03-06 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.
2024-02-07 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:
2023-10-25 09:05:00 - GlobeNewsWire
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
2023-09-13 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy. The new data build on SNS-101's preclinical safety and efficacy profile and provide additional insights into its conditionally active mechanism of action...
2023-08-30 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in the following investor conferences in September 2023:
2023-04-13 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors' at Canaccord Genuity's Horizons in Oncology Virtual Conference on Thursday, April 20th at 3:00 p.m. ET.
2023-03-14 16:35:00 - GlobeNewsWire
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL.
2023-02-14 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia, being held February 19-22, 2023 in Banff, Alberta, Canada. The presentation will be made by Sensei's Chief Scientific Officer, Dr. Edward van der Horst.
2022-11-02 07:30:00 - GlobeNewsWire
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.